How the Novartis Vymada Ruling Redraws India’s Battle for Affordable Heart Drugs

The world of medicine is often caught between two opposing truths. On one hand, patients need affordable drugs that can keep them alive, and on the other, pharmaceutical giants rely on patents to protect their research and profits. Rarely do these two truths sit peacefully together. India, with its history of challenging patent monopolies to ensure access to affordable medicines, has once again made headlines by revoking the patent on Novartis cardiac blockbuster Vymada. This decision by the Indian Patent Office (IPO) has the potential to reshape the future of heart care in the country, to shift the balance between global pharma powerhouses and local manufacturers, and to remind the world that India’s patent regime has always placed patients at the heart of its priorities.

Vymada, known globally as Entresto, is a drug prescribed widely for hypertension and heart failure. By combining sacubitril and valsartan, it addresses conditions that claim millions of lives each year. For Novartis, this therapy has been nothing short of a goldmine, bringing in around $7.8 billion in global sales last year alone. But in India, where the burden of heart disease is among the highest in the world and where out-of-pocket expenditure remains a cruel barrier for families, the story of Vymada has unfolded very differently. Here, its patent has been at the center of an intense legal war between the Swiss multinational and domestic drugmakers, and the outcome of that battle may well be a game changer for patients across the country.

The decision to revoke the patent came on September 12, delivered by Deputy Controller of Patents and Designs D Usha Rao. Novartis had failed to demonstrate any true innovation in the drug’s claimed “supramolecular complex.” The company’s submission, the order noted, lacked experimental data, comparative studies, or scientific reasoning that could prove enhanced therapeutic benefits beyond existing options. In other words, the patent claim did not meet the threshold of novelty and inventive step that Indian law demands. Without such proof, the claim was left vulnerable under the provisions of the Patents Act, 1970, particularly Section 3(d) i.e. a provision that has become synonymous with India’s refusal to allow evergreening of patents.

Section 3(d) has long been a thorn in the side of multinational drugmakers. It is the clause that prevents companies from filing patents for minor modifications of existing drugs without clear evidence of significantly improved efficacy. It came into the global spotlight back in 2013, when Novartis itself lost its case to protect the cancer drug Glivec. That ruling set the stage for India to emerge as the “pharmacy of the developing world,” ensuring that critical medicines could be made available in generic form at a fraction of the global price. With the Vymada decision, Section 3(d) has once again flexed its muscle, reinforcing India’s reputation as a country unwilling to compromise patient access for corporate exclusivity.

The implications of this ruling are immediate and far-reaching. For Indian patients, especially those struggling with the dual challenges of hypertension and heart failure, the opening up of the market means more affordable drugs. Generic manufacturers who had already ventured into the market at risk, including Natco, Torrent Pharma, MSN Labs, and Eris Lifesciences, now stand vindicated. With the legal cloud lifted, more players are expected to launch their own versions, driving down prices further. This competitive landscape could transform the economics of heart care in India, where the cost of long-term treatment has often forced families into debt or denial of care.

Companies such as IPCA and Micro Labs, backed by the Indian Pharmaceutical Alliance, had opposed the patent grant at the post-grant stage, arguing that it was nothing more than an attempt at evergreening. Their persistence has paid off, not only in terms of legal triumph but also in reinforcing the credibility of India’s homegrown pharma sector. For years, Indian firms have been accused by global giants of free-riding on their research investments. Yet, this case demonstrates that India’s patent challenges are not about undercutting innovation, they are about ensuring that innovation is genuine, substantial, and truly beneficial to patients.

For Novartis, the ruling is undoubtedly a blow. Having filed for the patent in 2007 and finally receiving approval in December 2022, the company had hoped to secure a long run of market exclusivity in India. Instead, less than a year later, the protection has been stripped away. Legal observers have pointed out that Novartis did not even participate in the final hearing, relying only on written submissions. Whether this was a sign of overconfidence, strategic calculation, or fatigue from years of litigation is anyone’s guess. What seems certain is that Novartis will challenge the revocation in court, setting the stage for yet another round of legal battles. But for now, the momentum rests firmly with the generics.

The larger story, however, goes beyond Novartis and Vymada. This case is a reminder of the philosophical tug-of-war that has defined India’s pharmaceutical landscape for decades. Should patents be protected at all costs, in recognition of the billions of dollars global companies invest in drug development? Or should patents be scrutinized with special rigor in countries like India, where access to affordable medicines is literally a matter of life and death for millions? India has consistently chosen the latter, crafting a patent regime that prioritizes public health while still allowing room for genuine innovation to be rewarded. This balance is delicate, often contentious, but deeply necessary in a country where the healthcare system is stretched and inequities run deep.

At the same time, the ruling shines a light on the strategies used by multinational corporations to extend their monopolies through incremental tweaks to existing drugs. The practice of evergreening is not unique to Novartis; it is a widespread tactic in the industry, justified by companies as a way to recoup massive R&D investments. But critics argue that without rigorous checks like Section 3(d), patients are left paying exorbitant prices for drugs that offer little to no added value. In India, where public funding for healthcare is limited and insurance coverage remains patchy, such practices can effectively shut out vast segments of the population from accessing essential therapies.

The future of Vymada in India now hinges on how quickly generic competition intensifies and how aggressively Novartis pursues legal recourse. But regardless of what comes next, the precedent set by this ruling is likely to influence battles over other drugs in the pipeline. Global pharmaceutical giants, already wary of India’s patent regime, may tread more cautiously, while domestic companies may feel emboldened to challenge questionable claims with renewed vigor.

For policymakers, the challenge will be to ensure that the momentum created by this ruling translates into tangible benefits for patients. Lower prices must reach the shelves quickly, and regulatory bottlenecks must not delay the availability of quality generics. Doctors must be kept informed and encouraged to prescribe affordable alternatives, while patients must be educated about the safety and efficacy of generics to overcome the perception gap that often lingers around them.

In the international arena, India’s stance is likely to reignite debates around intellectual property rights, trade agreements, and the balance between innovation and access. Global pharmaceutical lobbies have long criticised Section 3(d) as being too restrictive, arguing that it disincentivises innovation and undermines the business case for investing in the Indian market. Yet, for countries across Asia, Africa, and Latin America that depend on India for affordable medicines, this ruling will be celebrated as another example of India standing firm against corporate monopolies. Once again, India has positioned itself not only as the defender of its own patients but as a lifeline for much of the developing world.

The clash between innovation and access will not end here. More disputes will follow, more patents will be challenged, and more companies will test the resilience of India’s system. But the message from this case is clear that in India, the right to health is not negotiable, and no monopoly can stand in the way of making lifesaving drugs accessible to those who need them the most.

#healthvoice #AffordableHealthcare #AccessToMedicines #IndiaPharma #PatentRevocation #GenericMedicines #HealthcareForAll #PatientFirst #PharmaNews #Novartis #DrugPricing #RightToHealth #PharmaReform #InnovationVsAccess